{
    "root": "bb67792d-40d6-4192-96a7-963b100e17f9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eplerenone",
    "value": "20210204",
    "ingredients": [
        {
            "name": "EPLERENONE",
            "code": "6995V82D0B"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "Eplerenone tablets are an aldosterone antagonist indicated for: Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 )",
    "contraindications": "HFrEF Post-MI: Initiate treatment with 25 mg once daily. Titrate to maximum of 50 mg once daily within 4 weeks, as tolerated. Dose adjustments may be required based on potassium levels. ( 2.1 ) Hypertension: 50 mg once daily, alone or combined with other antihypertensive agents. For inadequate response, increase to 50 mg twice daily. Higher dosages are not recommended. ( 2.2 ) For all patients: Measure serum potassium before starting eplerenone tablets and periodically thereafter. ( 2.3 )",
    "warningsAndPrecautions": "Eplerenone Tablets are available containing 25 mg or 50 mg of eplerenone.\n                  The 25 mg tablets are yellow, film-coated, round, unscored tablets debossed with EP1 on one side of the tablet and M on the other side.  They are available as follows:\n                  NDC 66993-343-30bottles of 30 tablets\n                  NDC 66993-343-85bottles of 90 tablets\n                  The 50 mg tablets are yellow, film-coated, round, unscored tablets debossed with EP2 on one side of the tablet and M\n                      on the other side. They are available as follows: \n                  NDC 66993-344-30bottles of 30 tablets\n                  NDC 66993-344-85bottles of 90 tablets\n                  \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.",
    "adverseReactions": "For All Patients: Eplerenone tablets are contraindicated in all patients with: \n                  \n                     serum potassium > 5.5 mEq/L at initiation, \n                     creatinine clearance ≤ 30 mL/min, or \n                     concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].\n                  \n                  \n                     For Patients Treated for Hypertension: Eplerenone tablets are contraindicated for the treatment of hypertension in patients with: \n                  \n                     type 2 diabetes with microalbuminuria, \n                     serum creatinine > 2.0 mg/dL in males or > 1.8 mg/dL in females, \n                     creatinine clearance < 50 mL/min, or \n                     concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1), Adverse Reactions (6.2), Drug Interactions (7), and Clinical Pharmacology (12.3)]."
}